Advocated for clarity and fairness in the regulation of pharmaceutical compounding by the Food and Drug Administration (FDA), including issues related to compliance with Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
2025 · 2nd Quarter (Apr 1 - June 30)
EMPOWER PHARMACY
Filed by FRONTLINE GOVERNMENT RELATIONS.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 21, 2025
- Income
- $45,000.00
- Expenses
- Not reported
- Registrant
- FRONTLINE GOVERNMENT RELATIONS
- Client
- EMPOWER PHARMACY
- Filing UUID
- 0c7a6d16-f01e-42e8-82f7-8972afaaff91
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Advocated for regulatory clarity and proportional enforcement in the oversight of outsourcing facility manufacturing under Section 503B of the Federal Food, Drug, and Cosmetic Act.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.